CAJ | 학술논문

目的：比较胸腔内注射尿激酶或糖皮质激素治疗结核性胸膜炎的疗效性和安全性。方法：计算机检索Medline、Embase、Cochrane-library、Web of science、中国生物医学文献数据库、中文科技期刊数据库、中国知网、万方医学网数据库，并辅以手工检索从建库起至2014年11月关于胸腔内注入尿激酶或激素治疗结核性胸膜炎疗效比较的随机对照研究文献，采用RevMan 5．2．3软件行数据分析。结果：纳入5项研究，Meta分析显示，尿激酶组和激素组的胸水完全吸收时间（RR＝0．48，P＝0．22）、胸膜增厚发生率（RR＝0．67，P＝0．06）及不良反应（RR＝1．17，P＝0．70）差异无统计学意义；胸膜厚度有明显异质性（I2＝91％），不予Meta合并。结论：胸腔内注入尿激酶或激素治疗结核性胸膜炎疗效和安全性比较无显著差异。
목적：비교흉강내주사뇨격매혹당피질격소치료결핵성흉막염적료효성화안전성。방법：계산궤검색Medline、Embase、Cochrane-library、Web of science、중국생물의학문헌수거고、중문과기기간수거고、중국지망、만방의학망수거고，병보이수공검색종건고기지2014년11월관우흉강내주입뇨격매혹격소치료결핵성흉막염료효비교적수궤대조연구문헌，채용RevMan 5．2．3연건행수거분석。결과：납입5항연구，Meta분석현시，뇨격매조화격소조적흉수완전흡수시간（RR＝0．48，P＝0．22）、흉막증후발생솔（RR＝0．67，P＝0．06）급불량반응（RR＝1．17，P＝0．70）차이무통계학의의；흉막후도유명현이질성（I2＝91％），불여Meta합병。결론：흉강내주입뇨격매혹격소치료결핵성흉막염료효화안전성비교무현저차이。
Objective:To evaluate the efficacy and safety of intrapleural urokinase or glucocorticoid in treatment of tuberculous pleural effusion .Methods:All randomized controlled trials , which studied comparison of effects between intrapleural urokinase or glusocorticoid for tuberculous pleural effusion , were searched from Medline , Embase ,Cochrane-library , Web of science , Chinese Biomedical Literature Database , Chinese National Knowledge Infrastructure ,Chinese Scientific Journal Database ,Wanfang Med Online Database up to November 2014 .All were searched by manual and computer retrieval .RevMan 5 .2 .3 was used for data analysis .Results: Five literatures were included in this study .No statistical difference was found between urokinase group and glucocorticoid group on hydrothorax absorption days (RR=0.48,P=0.22), the incidence of pleural thickening (RR=0.67,P=0.06) and adverse reaction(RR=1.17,P=0.70).But due to significant heterogeneity , the description rather than Meta-analysis was managed on index of thickness of pleura ( I2 =91%) .Conclusion: There is no significant difference between intrapleural urokinase and glucocorticoid on effects and safety in the treatment of tuberculous pleural effusion .